Huerta M, de Aluja A S, Fragoso G, Toledo A, Villalobos N, Hernández M, Gevorkian G, Acero G, Díaz A, Alvarez I, Avila R, Beltrán C, Garcia G, Martinez J J, Larralde C, Sciutto E
Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico.
Vaccine. 2001 Oct 12;20(1-2):262-6. doi: 10.1016/s0264-410x(01)00249-3.
Taenia solium cysticercosis seriously affects human health when localised in the central nervous system (CNS) and causes great economic loss in pig husbandry in rural areas of endemic countries. Increasing the resistance to the parasite in the obligatory host pig may help in curbing transmission. Three synthetic peptides based on protein sequences of the murine parasite Taenia crassiceps, which had previously been shown to induce protection in mice against homologous challenge, were tested as a vaccine against T. solium cysticercosis in pigs. Vaccinated and unvaccinated piglets (240 in all) were distributed in pairs among the peasants' households of two rural villages in Mexico in which 14% of the native pigs were cysticercotic. Ten to twelve months later, the effect of vaccination was evaluated at necropsy. Vaccination decreased the total number of T. solium cysticerci (98.7%) and reduced the prevalence (52.6%). The natural challenge conditions used in this field trial strengthen the likelihood of successful transmission control to both pig and human through a large-scale pig vaccination program. We believe this is a major contribution in anticysticercosis vaccine development as these rather simple yet protective peptides are potentially more cost-effective to produce and less variable in results than antigens that are more complex.
猪带绦虫囊尾蚴病定位于中枢神经系统(CNS)时会严重影响人类健康,并在流行国家的农村地区给养猪业造成巨大经济损失。提高终末宿主猪对该寄生虫的抵抗力可能有助于控制传播。三种基于小鼠寄生虫肥胖带绦虫蛋白质序列的合成肽,此前已证明可诱导小鼠对同源攻击产生保护作用,作为抗猪带绦虫囊尾蚴病疫苗在猪身上进行了测试。将接种疫苗和未接种疫苗的仔猪(共240头)成对分配到墨西哥两个农村村庄的农户中,其中14%的本地猪患有囊尾蚴病。10至12个月后,在尸检时评估疫苗接种效果。接种疫苗减少了猪带绦虫囊尾蚴的总数(98.7%)并降低了患病率(52.6%)。该现场试验中使用的自然感染条件增加了通过大规模猪疫苗接种计划成功控制猪和人类传播的可能性。我们认为这是抗囊尾蚴病疫苗开发的一项重大贡献,因为这些相当简单但具有保护作用的肽在生产上可能更具成本效益,且结果的变异性比更复杂的抗原更小。